Cargando…
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center
Patients with metastatic breast cancer (MBC) refractory to standard of care therapies have a poor prognosis. The purpose of this study was to assess patient characteristics and clinical outcomes for patients with MBC treated on phase I clinical trials. We performed a retrospective review of all pati...
Autores principales: | Weiss, Jennifer A., Nicklawsky, Andrew, Kagihara, Jodi A., Gao, Dexiang, Fisher, Christine, Elias, Anthony, Borges, Virginia F., Kabos, Peter, Davis, Sarah L., Leong, Stephen, Eckhardt, Sue Gail, Diamond, Jennifer R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724484/ https://www.ncbi.nlm.nih.gov/pubmed/33063469 http://dx.doi.org/10.1002/cam4.3487 |
Ejemplares similares
-
Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials
por: Schreiber, Anna R., et al.
Publicado: (2021) -
Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval
por: Stoen, Ericson, et al.
Publicado: (2021) -
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021) -
Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Shay, Rebecca C., et al.
Publicado: (2020) -
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
por: Diamond, Jennifer R., et al.
Publicado: (2018)